Advisory Committee on the Medical Uses of Isotopes: Meeting Notice, 11950-11951 [2017-03733]
Download as PDF
11950
Federal Register / Vol. 82, No. 37 / Monday, February 27, 2017 / Notices
Part 40 of title 10 of the Code of
Federal Regulations (10 CFR),
authorizes the NRC to issue a license to
AUC for its Reno Creek Uranium In-Situ
Recovery (ISR) Facility in Campbell
County, Wyoming. Under conditions in
the license, the Source and Byproduct
Materials License SUA–1602 authorizes
AUC to operate its facilities as proposed
in its license application, as amended,
and to possess uranium source and
byproduct material at the Reno Creek
ISR Facility. The NRC’s ROD that
supports the decision to approve AUC’s
license application for the Reno Creek
ISR Facility and to issue the license is
available in ADAMS under Accession
No. ML17011A195.
By letter dated October 3, 2012, AUC,
LLC submitted a license application to
the NRC for a Source and Byproduct
Materials License for the in-situ
1 ......................
2 ......................
3 ......................
4
5
6
7
8
9
......................
......................
......................
......................
......................
......................
10 ....................
11 ....................
12 ....................
13 ....................
[FR Doc. 2017–03807 Filed 2–24–17; 8:45 am]
BILLING CODE 7590–01–P
NUCLEAR REGULATORY
COMMISSION
Advisory Committee on the Medical
Uses of Isotopes: Meeting Notice
U.S. Nuclear Regulatory
Commission.
mstockstill on DSK3G9T082PROD with NOTICES
AGENCY:
Notice of meeting.
The U.S. Nuclear Regulatory
Commission will convene a meeting of
the Advisory Committee on the Medical
Uses of Isotopes (ACMUI) on April 26–
27, 2017. A sample of agenda items to
VerDate Sep<11>2014
review process. The NRC’s Safety
Evaluation Report documenting its
review of AUC’s application was
completed on September 30, 2016. The
NRC issued its final environmental
impact statement on December 16, 2016
In accordance with 10 CFR 2.390 of
the NRC’s ‘‘Rules of Practice,’’ the
details with respect to this action,
including the Safety Evaluation Report
and accompanying documentation and
license, are available online in the
ADAMS Public Documents collection at
https://www.nrc.gov/reading-rm/
adams.html. From this site, you can
access the NRC’s Agencywide
Document Access and Management
System (ADAMS), which provides text
and image files of the NRC’s public
documents.
The ADAMS accession numbers for
the documents related to this notice are:
Generic Environmental Impact Statement for In-Situ Leach Uranium Milling Facilities, May 2009 ...............
AUC, LLC’s Application, October 3, 2012 ......................................................................................................
NRC email informing AUC that License Application Added to ADAMS and Deferral of Acceptance Review, November 30, 2012.
NRC Request for Additional Information .........................................................................................................
Round 1—Response to Request for Additional Information, June 13, 2012 .................................................
NRC Results of Round 1 RAI Response Package, September 9, 2014 .......................................................
AUC Revised RAI Response Package, December 23, 2014 .........................................................................
Safety Evaluation Report, September 30, 2016 .............................................................................................
Environmental Impact Statement for the Reno Creek ISR Project in Campbell County, Wyoming, Supplement to the Generic Environmental Impact Statement for In-Situ Leach Uranium Milling Facilities, Draft
Report for Public Comments, June 30, 2016.
NUREG–1910, Suppl. 6, Environmental Impact Statement for the Reno Creek ISR Project in Campbell
County, Wyoming, Supplement to the Generic Environmental Impact Statement for In-Situ Leach Uranium Milling Facilities, Final Report, December 2016.
Source and Byproduct Materials License SUA–1602, February 16, 2017 .....................................................
NRC Staff’s Record of Decision, February 03, 2017 ......................................................................................
Safety Evaluation Report, Revision 1, February 16, 2017 .............................................................................
Dated at Rockville, Maryland, this 16th day
of February 2017.
For the Nuclear Regulatory Commission.
Andrea Kock,
Deputy Director, Division of
Decommissioning, Uranium Recovery and
Waste Programs, Office of Nuclear Material
Safety and Safeguards.
ACTION:
extraction and recovery of uranium at
its Reno Creek ISR Project in Campbell
County, Wyoming. On November 30,
2012, the NRC staff acknowledged
receipt of the application and noted that
the application was placed in ADAMS)
under Accession No. ML122890785.
The NRC staff also noted that it could
not commence its acceptance review
until March 2013. The staff commenced
the acceptance review in March 2013,
and notified AUC on June 18, 2013, that
the NRC staff had completed its
acceptance review and found the
application acceptable for detailed
technical (safety) and environmental
review. In addition to the application,
the NRC staff held multiple public
meetings with AUC to discuss various
issues and submitted detailed requests
for additional information to which
AUC provided responses during the
20:23 Feb 24, 2017
Jkt 241001
be discussed during the public session
includes: (1) An update on medicalrelated events; (2) a presentation by
Elekta on the physical presence
requirements for the Leksell Gamma
Knife® IconTM; (3) an update on
Category 3 source security and
accountability evaluation initiatives; (4)
a discussion on the training and
experience requirements for authorized
individuals for various modalities; (5)
an update on the patient release project;
(6) a discussion on the reporting of
medical events for various modalities;
(7) a discussion on patient intervention;
and (8) a discussion on medical event
reporting and impact on safety culture.
The agenda is subject to change. The
current agenda and any updates will be
available at https://www.nrc.gov/readingrm/doc-collections/acmui/meetings/
2017.html or by emailing Ms. Michelle
Smethers at the contact information
below.
Purpose: Discuss issues related to title
10 of the Code of Federal Regulations
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
ML091530075
ML122890785
ML12349A262
ML13365A110
ML14169A452
ML14247A276
ML15002A077
ML16237A141
ML16181A082
ML16342A973
ML16364A219
ML17011A195
ML16364A227
(10 CFR) Part 35 Medical Use of
Byproduct Material.
Date and Time for Open Sessions:
April 26, 2017, from 8:00 a.m. to 2:30
p.m. and April 27, 2017, from 8:00 a.m.
to 3:45 p.m.
Date and Time for Closed Sessions:
April 26, 2017, from 7:30 a.m. to 8:00
a.m.
Address for Public Meeting: U.S.
Nuclear Regulatory Commission, Two
White Flint North Building, Room T2–
B3, 11545 Rockville Pike, Rockville,
Maryland 20852.
Any member of
the public who wishes to participate in
the meeting in person or via phone
should contact Ms. Smethers using the
information below. The meeting will
also be webcast live: https://
video.nrc.gov/.
PUBLIC PARTICIPATION:
CONTACT INFORMATION: Michelle
Smethers, email: michelle.smethers@
nrc.gov, telephone: (301) 415–0168.
E:\FR\FM\27FEN1.SGM
27FEN1
Federal Register / Vol. 82, No. 37 / Monday, February 27, 2017 / Notices
Conduct of the Meeting
Philip O. Alderson, M.D., will chair
the meeting. Dr. Alderson will conduct
the meeting in a manner that will
facilitate the orderly conduct of
business. The following procedures
apply to public participation in the
meeting:
1. Persons who wish to provide a
written statement should submit an
electronic copy to Ms. Smethers using
the contact information listed above. All
submittals must be received by April 21,
2017, and must pertain to the topic on
the agenda for the meeting.
2. Questions and comments from
members of the public will be permitted
during the meeting, at the discretion of
the Chairman.
3. The draft transcript and meeting
summary will be available on ACMUI’s
Web site https://www.nrc.gov/readingrm/doc-collections/acmui/meetings/
2017.html on or about June 14, 2017.
4. Persons who require special
services, such as those for the hearing
impaired, should notify Ms. Smethers of
their planned attendance.
This meeting will be held in
accordance with the Atomic Energy Act
of 1954, as amended (primarily Section
161a); the Federal Advisory Committee
Act (5 U.S.C. App); and the
Commission’s regulations in 10 CFR
part 7.
Dated at Rockville, Maryland, this 21st day
of February, 2017.
For the Nuclear Regulatory Commission.
Andrew L. Bates,
Advisory Committee Management Officer.
[FR Doc. 2017–03733 Filed 2–24–17; 8:45 am]
BILLING CODE 7590–01–P
OVERSEAS PRIVATE INVESTMENT
CORPORATION
Sunshine Act Meeting Notice
Thursday, December 8,
2016, 2 p.m. (OPEN Portion), 2:15 p.m.
(CLOSED Portion).
PLACE: Offices of the Corporation,
Twelfth Floor Board Room, 1100 New
York Avenue NW., Washington, DC.
STATUS: Meeting OPEN to the Public
from 2 p.m. to 2:15 p.m. Closed portion
will commence at 2:15 p.m. (approx.).
mstockstill on DSK3G9T082PROD with NOTICES
TIME AND DATE:
Matters to be Considered
1. President’s Report
2. Minutes of the Open Session of the
September 15, 2016 Board of Directors
Meeting
Further Matters to be Considered
(Closed to the Public 2:15 P.M.)
1. Insurance Project—Jordan
VerDate Sep<11>2014
20:23 Feb 24, 2017
Jkt 241001
2. Insurance Project—Israel
3. Finance Project—Africa, South Asia
4. Finance Project—Africa
5. Minutes of the Closed Session of the
September 15, 2016 Board of Directors
Meeting
6. Reports
7. Pending Projects
CONTACT PERSON FOR MORE INFORMATION:
Information on the meeting may be
obtained from Catherine F.I. Andrade at
(202) 336–8768, or via email at
Catherine.Andrade@opic.gov.
Dated: November 9, 2016.
Catherine F.I. Andrade,
Corporate Secretary, Overseas Private
Investment Corporation.
[FR Doc. 2017–03905 Filed 2–23–17; 4:15 pm]
BILLING CODE 3210–01–P
SECURITIES AND EXCHANGE
COMMISSION
[Release No. 34–80076; File No. SR–
NYSEArca–2016–89]
Self-Regulatory Organizations; NYSE
Arca, Inc; Notice of Designation of
Longer Period for Commission Action
on Proceedings To Determine Whether
To Approve or Disapprove a Proposed
Rule Change, as Modified by
Amendment Nos. 1–4, To Amend the
Co-location Services Offered by the
Exchange To Add Certain Access and
Connectivity Fees
February 22, 2017.
On August 16, 2016, NYSE Arca, Inc.
(‘‘NYSE Arca’’ or the ‘‘Exchange’’) filed
with the Securities and Exchange
Commission (‘‘Commission’’), pursuant
to Section 19(b)(1) of the Securities
Exchange Act of 1934 (‘‘Act’’) 1 and Rule
19b–4 thereunder,2 a proposed rule
change to (1) provide additional
information regarding access to various
NYSE trading and execution services
and establish fees for connectivity to
certain NYSE market data feeds; and (2)
provide and establish fees for
connectivity to data feeds from third
party markets and other content service
providers; access to the trading and
execution services of Third Party
markets and other content service
providers; connectivity to Depository
Trust & Clearing Corporation services;
connectivity to third party testing and
certification feeds; and the use of virtual
control circuits by Users in the Data
Center.
The Commission published the
proposed rule change for comment in
the Federal Register on August 26,
1 15
2 17
PO 00000
U.S.C. 78s(b)(1).
CFR 240.19b–4.
Frm 00061
Fmt 4703
Sfmt 4703
11951
2016.3 The Commission received no
comments in response to the proposed
rule change.4 On October 4, 2016, the
Commission extended the time period
within which to approve the proposed
rule change, disapprove the proposed
rule change, or institute proceedings to
determine whether to approve or
disapprove the proposed rule change to
November 24, 2016.5
On November 2, 2016, the Exchange
filed Amendment No. 1 to the proposed
rule change.6 On November 29, 2016,
the Commission instituted proceedings
to determine whether to approve or
disapprove the proposed rule change, as
modified by Amendment No. 1.7
Following the Order Instituting
Proceedings, the Commission received
several additional comment letters
regarding the proposed rule change.8 On
December 9, 2016, the Exchange filed
Amendment No. 2 to the proposed rule
change and on December 13, 2016 also
3 See Securities Exchange Act Release No. 34–
78628 (August 22, 2016), 81 FR 59004 (‘‘Notice’’).
4 The Commission notes that it did receive one
comment letter on a related filing, NYSE–2016–45
(the ‘‘NYSE Companion Filing’’),which is equally
relevant to this filing. See letter to Brent J. Fields,
Secretary, Commission, from John Ramsay, Chief
Market Policy Officer, Investors Exchange LLC
(IEX), dated September 9, 2016 (‘‘IEX Letter’’).
On September 23, 2016, the NYSE submitted a
response (‘‘Response Letter I’’).
5 See Securities Exchange Act Release No. 34–
78967 (September 28, 2016), 81 FR 68480.
6 Amendment No. 1 is available on the
Commission’s Web site at https://www.sec.gov/
comments/sr-nysearca-2016-89/nysearca2016891.pdf.
7 See Securities Exchange Act Release 34-79379
(November 22, 2016), 81 FR 86036.
8 See letter to Brent J. Fields, Commission, from
Melissa MacGregor, Managing Director and
Associate General Counsel, SIFMA, dated December
12, 2016 (‘‘SIFMA Letter I’’); letter to Brent J. Fields,
Commission, from Joe Wald, Chief Executive
Officer, Clearpool Group, dated December 16, 2016
(‘‘Clearpool Letter’’); letter to Brent J. Fields,
Secretary, Commission, from John Ramsay, Chief
Market Policy Officer, Investors Exchange LLC
(IEX), dated December 21, 2016 (‘‘IEX Letter II’’);
letter to Brent J. Fields, Commission, from Melissa
MacGregor, Managing Director and Associate
General Counsel, SIFMA, dated February 6, 2017
(‘‘SIFMA Letter II’’). All comments received by the
Commission on the proposed rule change are
available on the Commission’s Web site at: https://
www.sec.gov/comments/sr-nysearca-2016-89/
nysearca201689.shtml.
The Commission notes that it did receive
additional comment letters on the NYSE
Companion Filing which are equally relevant to this
filing. See letter to Brent J. Fields, Commission,
from Adam C. Cooper, Senior Managing Director
and Chief Legal Officer, Citadel Securities, dated
December 12, 2016 (‘‘Citadel Letter’’); letter to Brent
J. Fields, Commission, from David L. Cavicke, Chief
Legal Officer, Wolverine LLC (‘‘Wolverine Letter’’);
letter to Bent J. Fields, Secretary, Commission, from
Stefano Durdic, Managing Director, R2G Services,
LLC, dated January 21, 2017 (‘‘R2G Letter’’). All
comments received by the Commission on the
NYSE Companion Filing are available on the
Commission’s Web site at: https://www.sec.gov/
comments/sr-nyse-2016-45/nyse201645.shtml.
E:\FR\FM\27FEN1.SGM
27FEN1
Agencies
[Federal Register Volume 82, Number 37 (Monday, February 27, 2017)]
[Notices]
[Pages 11950-11951]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03733]
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Advisory Committee on the Medical Uses of Isotopes: Meeting
Notice
AGENCY: U.S. Nuclear Regulatory Commission.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
The U.S. Nuclear Regulatory Commission will convene a meeting of
the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on April
26-27, 2017. A sample of agenda items to be discussed during the public
session includes: (1) An update on medical-related events; (2) a
presentation by Elekta on the physical presence requirements for the
Leksell Gamma Knife[supreg] IconTM; (3) an update on
Category 3 source security and accountability evaluation initiatives;
(4) a discussion on the training and experience requirements for
authorized individuals for various modalities; (5) an update on the
patient release project; (6) a discussion on the reporting of medical
events for various modalities; (7) a discussion on patient
intervention; and (8) a discussion on medical event reporting and
impact on safety culture. The agenda is subject to change. The current
agenda and any updates will be available at https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2017.html or by emailing Ms. Michelle
Smethers at the contact information below.
Purpose: Discuss issues related to title 10 of the Code of Federal
Regulations (10 CFR) Part 35 Medical Use of Byproduct Material.
Date and Time for Open Sessions: April 26, 2017, from 8:00 a.m. to
2:30 p.m. and April 27, 2017, from 8:00 a.m. to 3:45 p.m.
Date and Time for Closed Sessions: April 26, 2017, from 7:30 a.m.
to 8:00 a.m.
Address for Public Meeting: U.S. Nuclear Regulatory Commission, Two
White Flint North Building, Room T2-B3, 11545 Rockville Pike,
Rockville, Maryland 20852.
PUBLIC PARTICIPATION: Any member of the public who wishes to
participate in the meeting in person or via phone should contact Ms.
Smethers using the information below. The meeting will also be webcast
live: https://video.nrc.gov/.
CONTACT INFORMATION: Michelle Smethers, email:
michelle.smethers@nrc.gov, telephone: (301) 415-0168.
[[Page 11951]]
Conduct of the Meeting
Philip O. Alderson, M.D., will chair the meeting. Dr. Alderson will
conduct the meeting in a manner that will facilitate the orderly
conduct of business. The following procedures apply to public
participation in the meeting:
1. Persons who wish to provide a written statement should submit an
electronic copy to Ms. Smethers using the contact information listed
above. All submittals must be received by April 21, 2017, and must
pertain to the topic on the agenda for the meeting.
2. Questions and comments from members of the public will be
permitted during the meeting, at the discretion of the Chairman.
3. The draft transcript and meeting summary will be available on
ACMUI's Web site https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2017.html on or about June 14, 2017.
4. Persons who require special services, such as those for the
hearing impaired, should notify Ms. Smethers of their planned
attendance.
This meeting will be held in accordance with the Atomic Energy Act
of 1954, as amended (primarily Section 161a); the Federal Advisory
Committee Act (5 U.S.C. App); and the Commission's regulations in 10
CFR part 7.
Dated at Rockville, Maryland, this 21st day of February, 2017.
For the Nuclear Regulatory Commission.
Andrew L. Bates,
Advisory Committee Management Officer.
[FR Doc. 2017-03733 Filed 2-24-17; 8:45 am]
BILLING CODE 7590-01-P